pp-126 Concentrate for solution for infusion
Dossier type
CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Parkinson's disease (disease-modifying therapy; early-stage PD)
Clinical stage: Phase 2
Modality: Biologic (humanised IgG1 monoclonal antibody)
Mechanism / Target: Selectively binds and neutralises toxic α-synuclein oligomers and protofibrils; does not target monomeric α-synuclein; reduces propagation of pathological aggregates
Route / form: Intravenous or subcutaneous injection
Differentiation: High selectivity for toxic oligomers vs monomers may improve safety profile; differentiated epitope from other anti-α-syn programmes (Prasinezumab, Sinebiname)
Manufacturer #39163
Clinical-stage neuroscience company focused on disease modification in neurodegenerative disorders. Specialises in antibody therapies targeting protein aggregation in Parkinson's and Alzheimer's disease. Pursues global development with wholly owned key assets.